Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis
Saadeldin, Mona Kamal; Abdel-Aziz, Amal Kamal; Abdellatif, Ahmed;
Abstract
Immunotherapy is the newest approach to combat cancer. It can be achieved using several strategies, among which is the dendritic cell (DC) vaccine therapy. Several clinical trials are ongoing using DC vaccine therapy either as a sole agent or in combination with other interventions to tackle different types of cancer. Immunotherapy can offer a potential treatment to coronavirus disease 2019 (COVID-19) the worst pandemic facing this generation, a disease with deleterious effects on the health and economic systems worldwide. We hypothesize that DC vaccine therapy may provide a potential treatment strategy to help combat COVID-19. Cancer patients are at the top of the vulnerable population owing to their immune-compromised status. In this review, we discuss DC vaccine therapy in the light of the body's immunity, cancer, and newly emerging infections such as COVID-19 in hopes of better-customized treatment options for patients with multiple comorbidities.
Other data
Title | Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis | Authors | Saadeldin, Mona Kamal; Abdel-Aziz, Amal Kamal ; Abdellatif, Ahmed | Keywords | Advantages; COVID-19; Cancer; Combination therapy; Dendritic cell vaccine; Disadvantages; Immunotherapy | Issue Date | Jan-2021 | Publisher | CHURCHILL LIVINGSTONE | Journal | Medical hypotheses | ISSN | 03069877 | DOI | 10.1016/j.mehy.2020.110365 | PubMed ID | 33221134 | Scopus ID | 2-s2.0-85096406487 | Web of science ID | WOS:000612262600025 |
Attached Files
File | Description | Size | Format | Existing users please Login |
---|---|---|---|---|
1-s2.0-S0306987720332564-main.pdf | 1.7 MB | Adobe PDF | Request a copy |
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.